Project Grant R44AR084998
Award Date
8/21/24
Completion Date
7/31/26
Dollars Obligated
$999K
Funding Federal Agency
National Institute of Neurological Disorders and Stroke
Awarding Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and...
The National Institute on Drug Abuse (NIDA) awarded a $591,842 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Rebel Medicine Inc., a biotechnology company in Salt Lake City, Utah. The grant aims to develop and evaluate a long-acting injectable local anesthetic formulation using novel lipophilic salts to provide extended pain relief after surgery and reduce the need for opioid medications. The project will characterize the safety and efficacy of Rebel Medicine's...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,505,537 to The Leland Stanford Junior University to develop a focused ultrasound (FUS) device for noninvasive, peripheral nerve blockade to manage acute pain. The goal is to provide an alternative to opioids and current peripheral nerve block techniques, which have significant limitations in acute pain management. The...
The University of Miami is conducting a research project under a $1,109,446 Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). The project, funded through the Drug Abuse and Addiction Research Programs (CFDA 93.279), aims to develop a novel non-opioid analgesic based on gene therapy targeting the carbonic anhydrase-8 (CA8) protein to treat chronic pain associated with knee osteoarthritis. The...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...
This $1,559,917 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop a topical neurokinin-1 receptor (NK1R) antagonist as a non-addictive analgesic treatment for chronic ocular pain. The key objectives are to assess the analgesic efficacy of the NK1R antagonist and determine its effects on the ocular surface-trigeminal ganglion neurosensory pathway. The project is...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $675,107 to Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The research aims to design and synthesize a series of compounds that act as dual cannabinoid CB1 receptor allosteric agonist-positive allosteric modulators (AGO-PAMs) and...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $9,237,770 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Washington University to conduct research on the integrated mechanisms, phenotypes, and translational underpinnings of chronic pain after surgery. The project aims to gain mechanistic insights into peripheral and central biological processes that contribute to chronic postsurgical pain (CPSP) and understand how these...
This Project Grant award, with Federal Grant ID R21NS142685, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The $431,750 award to Michigan State University will fund research to explore the role of the chemokine CCL12 in alleviating post-operative pain. The project aims to test whether neutralizing CCL12 is effective and safe in reducing...